Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

@article{Ansari2010SunitinibIP,
  title={Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.},
  author={Jawaher Ansari and Arfeen Fatima and Kieran Fernando and Stuart Collins and Nicholas D James and Emilio Porfiri},
  journal={Oncology reports},
  year={2010},
  volume={24 2},
  pages={507-10}
}
Sunitinib is a novel, multi-targeted receptor tyrosine kinase inhibitor, which has demonstrated evidence of improved survival when compared to interferon (IFN)-alpha in patients with metastatic renal cell carcinoma (RCC). Recently published National Institute for Health and Clinical Excellence guidance recommends sunitinib as a first-line treatment option for patients with advanced and/or metastatic RCC. We assessed the efficacy and toxicity of sunitinib in an unselected group of patients with… CONTINUE READING
8 Citations
13 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…